The URL can be used to link to this page

Home My WebLink About06.16.26 Board Correspondence - FW_ U.S. Taxpayers Fund Research Behind Moderna's New mRNA-1010 Influenza Vaccine, Journal 'Natu.ATTENTION: This message originated from outside Butte County. Please exercise judgment before opening attachments, clicking on links, or replying.. From:Clerk of the Board To:Mutony, Heather Cc:Lee, Lewis Subject:Board Correspondence - FW: U.S. Taxpayers Fund Research Behind Moderna"s New mRNA-1010 Influenza Vaccine, Journal "Nature Immunology" Confirms Date:Tuesday, June 16, 2026 9:50:52 AM Attachments:image001.png Please see Board Correspondence - Lewis LeeAdministrative Technician - ConfidentialButte County Administration25 County Center Drive, Suite 200 • Oroville, CA 95965T: 530.552.3326www.buttecounty.ca.gov | lelee@buttecounty.ca.gov From: lance dreiss <lancedreiss@att.net> Sent: Tuesday, June 16, 2026 9:42 AM To: Shared Mailbox Clerk of the Board <pcbs@countyofplumas.com>; Assemblymember.Gallagher@assembly.ca.gov; Senator.Dahle@senate.ca.gov; davidhollister@countyofplumas.com; sheriff@countyofplumas.com; District Attorney <District_Attorney@buttecounty.ca.gov>; Nicolereinert@countyofplumas.com; Kitts, Melissa <mkitts@buttecounty.ca.gov>; Soderstrom, Monica <msoderstrom@buttecounty.ca.gov>; Durfee, Peter <PDurfee@buttecounty.ca.gov>; Ronald Owens <ronald@muzzledtruth.com>; Kimmelshue, Tod <TKimmelshue@buttecounty.ca.gov>; Pickett, Andy <APickett@buttecounty.ca.gov>; Connelly, Bill <BConnelly@buttecounty.ca.gov>; Teeter, Doug <DTeeter@buttecounty.ca.gov>; Beaudoin, Jarett <JBeaudoin@buttecounty.ca.gov>; Julie Threet <julie4butte5@gmail.com>; Waugh, Melanie <mwaugh@buttecounty.ca.gov>; Ritter, Tami <TRitter@buttecounty.ca.gov>; Teri DuBose <Teri.DuBose@mail.house.gov>; Clerk of the Board <clerkoftheboard@buttecounty.ca.gov>; Stephens, Brad J. <BStephens@buttecounty.ca.gov> Subject: Fwd: U.S. Taxpayers Fund Research Behind Moderna's New mRNA-1010 Influenza Vaccine, Journal 'Nature Immunology' Confirms Public Record “Researchers funded by the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) have published a study supporting Moderna’s experimental mRNA influenza vaccine, mRNA-1010, in the journal Nature Immunology. U.S. taxpayers are financing the work despite Moderna’s own scientists confirming in an earlier study that mRNA-1010 triggers six times more severe reactions for less than 1% absolute benefit.“ diana dreiss Begin forwarded message: From: Jon Fleetwood <jonfleetwood@substack.com> Date: June 16, 2026 at 8:38:14 AM PDT To: lancedreiss@att.net Subject: U.S. Taxpayers Fund Research Behind Moderna's New mRNA- 1010 Influenza Vaccine, Journal 'Nature Immunology' Confirms Reply-To: Jon Fleetwood <reply+3cfqxf&kcryl&&918612cdc74ef200c7b01e8eff5beb3b05d07fb6fb24a b45bbed14c1cdfeaa61@mg1.substack.com> Even though jab triggers six times more severe reactions for less than 1% absolute benefit.͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ Forwarded this email? Subscribe here for moreU.S. Taxpayers Fund Research Behind Moderna's New mRNA-1010 Influenza Vaccine, Journal 'Nature Immunology' Confirms Even though jab triggers six times more severe reactions for less than 1% absolute benefit. JON FLEETWOOD JUN 16 READ IN APP Researchers funded by the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID) have published a study supporting Moderna’s experimental mRNA influenza vaccine, mRNA-1010, in the journal Nature Immunology. U.S. taxpayers are financing the work despite Moderna’s own scientists confirming in an earlier study that mRNA-1010 triggers six times more severe reactions for less than 1% absolute benefit. Donate Upgrade to paid Share Follow us on Instagram @realjonfleetwood & Twitter/X @JonMFleetwood. If you value this reporting, consider upgrading to a paid subscription. For advertising & sponsorship opportunities, contact us by clicking below. Message Jon Fleetwood The new study examined immune responses among healthy adults who received Moderna’s investigational mRNA-based seasonal influenza vaccine and compared them to recipients of GlaxoSmithKline’s conventional flu vaccine, Fluarix. The funding section states: This work was supported in part by funding from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) and Moderna. The Genome Technology Access Center in the Department of Genetics at Washington University School of Medicine is partially supported by National Cancer Institute (NCI) Cancer Center Support Grant P30 CA91842 to the Siteman Cancer Center from the US NIH. A.H.E. discloses support for the research of this work from the NIAID (grants U01AI141990 and U01AI144616; contracts 75N93021C00014 and 75N93019C00051). H.C.M. discloses support from the NIAID (T32AI007172) and NCI (T32CA009547). J.L. discloses support for the research of this work from the NIH (grants P20GM113132 and P01AI089618). T.-G.Y. discloses support from the National Research Foundation of Korea funded by the Ministry of Education (RS-2024-00411420). J.D.B. discloses support for the research of this work from the NIAID (grant R01AI165821; contract 75N93021C00015). C.K. discloses support from the NIAID (T32AI083203). J.D.B. is an investigator of the Howard Hughes Medical Institute. F.K. discloses support for the research of this work from the NIAID (contract 75N93019C00051). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official view of the NIH or NIAID. The study’s findings are significant because they provide scientific evidence Moderna can cite in support of its mRNA influenza platform as the company continues development of mRNA-1010 and other mRNA-based respiratory vaccines. You can contact NIAID here, NIH here, and HHS here to voice opposition to taxpayer-funded research supporting drugs with more severe reactions and almost zero absolute benefit. Especially if those drugs are pushed on citizens during a government-declared outbreak. You can contact Moderna here. Problems With the Study The paper is overwhelmingly positive toward Moderna’s vaccine and is written to support the conclusion that mRNA-1010 produces a superior immune response. However, several limitations and findings in the paper may give readers reason to scrutinize the study’s optimistic conclusions: The study was observational rather than a randomized controlled trial, meaning participants were not randomly assigned to receive the vaccines. The paper’s most significant findings came from a small subgroup of participants. Only 13 Moderna vaccine recipients underwent the lymph-node sampling used to support many of the study’s headline conclusions. Some of the deeper immune-system analyses were conducted on an even smaller number of participants, limiting how broadly the results can be generalized. The researchers were not comparing identical vaccines. The paper acknowledges that Moderna’s vaccine and the conventional flu shot contained slightly different influenza strains, complicating direct comparisons. Despite reporting broader immune responses, the authors acknowledged that they “did not detect significant increases in their binding affinities” among the analyzed immune-cell clones. The study also found no significant advantage in hemagglutination- inhibition (HAI) titers, one of the traditional measures used to evaluate influenza vaccine responses. The study measured immune-system markers rather than real-world outcomes such as reductions in influenza infections, hospitalizations, or deaths. Participants were healthy adults between the ages of 20 and 50, meaning the with significant underlying health conditions. The Moderna paper reports biological differences between the vaccines, but several of its key conclusions are based on small participant groups, non-randomized observations, and immune-system measurements rather than direct clinical outcomes. Bottom Line U.S. taxpayers are funding research that Moderna can use to support and advance its new mRNA influenza vaccine. Even though the study’s most important findings are based largely on small participant groups, non-randomized observations, and laboratory immune markers rather than real-world reductions in influenza infections, hospitalizations, or deaths. The paper is openly optimistic about mRNA-1010 and promotes prolonged immune- system activity as a benefit. Yet the authors also acknowledge they found no significant improvement in antibody binding affinity and no significant advantage in a traditional influenza vaccine performance measure. At a minimum, the study demonstrates that taxpayer-funded NIH and NIAID researchers are helping build the scientific case for a pharmaceutical product that Moderna stands to profit from. Donate Upgrade to paid Share Follow us on Instagram @realjonfleetwood & Twitter/X @JonMFleetwood. If you value this reporting, consider upgrading to a paid subscription. For advertising & sponsorship opportunities, contact us by clicking below. Message Jon Fleetwood Moderna Confirms Its New mRNA-1010 Flu Shot Triggers 6 Times More Severe Reactions for Less Than 1% Absolute Benefit: 'New England Journal of Medicine' JON FLEETWOOD ·MAY 8 Read full story FDA Allows Public Comments on Moderna's New mRNA Influenza Vaccine MFLUSIVA (mRNA-1010) JON FLEETWOOD ·JUN 4 Read full story Moderna Begins Injecting 4,000 Adults with modRNA Bird Flu Pandemic Vaccine JON FLEETWOOD ·APR 22 Read full story DARPA Linked to COVID-19 Virus and Moderna Jab Creation Since 2012, Covered Up EcoHealth Gain-of-Function Research in 2021 JON FLEETWOOD ·NOVEMBER 22, 2024 Read full story Moderna Jab mRNA Enters Blood, Stays for Weeks—We Were Told It Wouldn't: Journal 'ACS Nano' JON FLEETWOOD ·DECEMBER 20, 2024 Read full story Infants Vaccinated with Moderna RSV mRNA Jab 3x More Likely to Develop RSV Disease Than Unvaccinated: FDA JON FLEETWOOD ·DECEMBER 12, 2024 Read full story You're currently a free subscriber to JonFleetwood.com. For the full experience, upgrade your subscription. Upgrade to paid LIKE COMMENT RESTACK © 2026 Jon Fleetwood 548 Market Street PMB 72296, San Francisco, CA 94104 Unsubscribe